Powered By
Thanks Wendy. You are a gem and a genius xxx
No they aren't the same. Treatment drugs for kras mutations are pretty thin. I think the 2 approved in the US are only g12c although they have been trying them on other kras mutations if other lines of treatment fail. I think I remember reading somewhere that there may be a 3rd targeted drugs in trials but again it was for g12c. It doesn't mean you can't get results through other treatment options just that there isn't a specific targeted drug for your mutation.
No, KRAS G12X and KRAS G12C mutations are not the same. The "C" in G12C specifically refers to a mutation where glycine is replaced by cysteine at position 12 in the KRAS protein. This specific mutation is important because there are FDA-approved targeted treatments for it, including sotorasib (Lumakras) and adagrasib Show Full Answer
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
